TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE3
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
- Status
- WITHDRAWN
- Phase
- PHASE2
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2